We are pleased to announce that the BMCS has made the appointments below:
2020/2021 BMCS Lectureship – Dr Elisabetta Chiarparin of AstraZeneca and Dr James Duffy of Medicines for Malaria Venture
2021/2022 BMCS Lectureship – Dr David Rees of Astex Pharmaceuticals
- Successful applications must be available to deliver up to six lectures at UK universities.
- Applications are invited from applicants at all stages in their career.
- Applicants should have made significant advances in the subject through new products or methods.
- Every two years, the Biological and Medicinal Chemistry Sector (BMCS) of the RSC seeks nominations of BMCS Lecturers in response to an advertisement publicising this opportunity. The selected Lecturers are each appointed for a one-year period.
Please contact Dr Andrew Stachulski directly with any queries or expressions of interest in staging a lecture.
2019/2020 BMCS Lectureship – Dr David Witty
The 2019/2020 BMCS Lecturer, Dr David Witty from Witnet R&D Consultancy, formerly Chemistry Director of Convergence Pharmaceuticals, is the sixth recipient of the BMCS Lectureship, awarded by the RSC’s Biological and Medicinal Chemistry Sector. He delivered his inaugural lecture “Drug Discovery Tomorrow: The Future Medicinal Chemist” at Burlington House, London, on 31st October 2019.
The Biological and Medicinal Chemistry Sector (BMCS) Lectureship was launched in 2014. At a time of many exciting changes in biological and medicinal chemistry, featuring new methodologies and targets, the committee wanted to appoint lecturers to inspire the next generation of medicinal chemists, whose lectures should therefore appeal, not only to postgraduate students and postdoctoral researchers, but also to undergraduates.
Every year, the Biological and Medicinal Chemistry Sector (BMCS) of the RSC appoints BMCS Lecturers for a two-year period from the nominations received in response to an advertisement publicising this opportunity. We live in a time when both the process of drug discovery and the business models by which it is funded have fundamentally altered in the last generation. Yet the great benefits of new medicines to society are clear to everyone, and the expectations for future advances, as we seek to treat currently untreatable conditions, are also great. These are exciting times to be involved in medicinal chemistry and we seek especially to inspire the next generation of medicinal chemists.
Dr Andrew Thomas (Helvetica Capital)
Dr Jamie Scott (Astra Zeneca)
Professor Stuart Conway (University of Oxford)
Professor Barry Potter (University of Bath)
Professor Michael Waring (Astra Zeneca, now University of Newcastle)